Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Needham

Tesla Stock Faces 'Critical Milestone' Ahead: Here's What Analysts Are Flagging As Next Key Catalyst

Can Tesla Inc‘s (NASDAQ:TSLA) audacious bet on autonomy and AI outmaneuver mounting market headwinds? As analysts hold their ground despite disappointing earnings, the electric vehicle giant faces a pivotal moment that could redefine its future trajectory.

Benzinga

NXP Semiconductors Sees No Big Ramp In End Demand, Yet Analysts Raise Price Targets

Shares of NXP Semiconductors NV (NASDAQ:NXPI) tanked in early trading on Wednesday, despite the company reporting upbeat second-quarter results.

Benzinga

Amazon To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets

On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.

Benzinga

Nvidia Will Restart H20 Shipments to China. Should You Buy NVDA Stock Here?

Nvidia stock remains in focus on hopes that the chipmaker will soon resume business in China. Needham raised its price target on NVDA shares to $200 on Wednesday.

Barchart

Will Fair Isaac's FICO Score Lose Market Share Due To VantageScore?

Fair Isaac Corp (NYSE:FICO) stock came under pressure on last week's announcement of Fannie Mae (OTC:FNMA) and Freddie Mac (OTC:FMCC) are now accepting VantageScore 4.0, which caused investor concerns around an erosion of the "FICO monopoly," according to Needham.

Benzinga

Alphabet Has Assets, Corporate Culture To Drive Valuation Higher, Says Bullish Analyst

Google-parent Alphabet Inc's (NASDAQ:GOOGL) strategic position and tech-first corporate culture drive upside to the stock valuation, according to Needham.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dear Netflix Stock Fans, Mark Your Calendars for July 17

The streaming giant will soon reveal its Q2 earnings, with all eyes on ad-tier growth and live content momentum.

Barchart

Dear Taiwan Semi Stock Fans, Mark Your Calendars for July 17

With earnings day nearing, all eyes are on July 17 as TSM stock fans brace to see whether Wall Street’s optimism will hold.

Barchart

Shopify Shares Are Up Monday: What's Going On?

Shopify Inc. (NASDAQ:SHOP) shares are trading higher Monday after Needham Company initiated coverage on the stock with a Buy rating and a $135 price target.

Benzinga

Uber To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Roku's Labor Efficiency Rose 34% Since 2021—Analyst Sees More Gains Ahead

Roku Inc. (NASDAQ:ROKU) is showing promising signs of growth as it enhances labor productivity, a key metric in today's competitive streaming industry, according to Needham.

Benzinga

Can Circle Stock Hit $250 in 2025?

Analysts are raising eyebrows and price targets alike. With strong backing and timing, can Circle actually touch $250 soon?

Barchart

Meta's Growth Sizzles, But Wait For A Pullback Before Buying In

Needham upgraded Meta Platforms, Inc. (NASDAQ:META) from Underperform to Hold on Thursday, but the analyst maintained a cautious stance on the stock as it trades near all-time highs.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Can Taiwan Semiconductor Stock Hit $270 in 2025?

Will TSM stock ride the AI wave all the way to Wall Street’s fresh Street-high target?

Benzinga

Affirm Holdings: Impact Of Walmart-Klarna Deal, 'Higher Mix Of Zeroes'

Affirm Holdings Inc.'s (NASDAQ:AFRM) fiscal 2026 revenues are likely to be impacted by Walmart Inc.'s (NYSE:WMT) volumes beginning to shift to Klarna-powered OnePay in the coming quarters, as well as a higher mix of non-interest-bearing transactions, according to Needham.

Benzinga

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Omada Health Analysts Say 'Buy' — While It's Still Below IPO Price

Canaccord Genuity and Needham analysts initiate coverage of Omada Health Inc (NASDAQ:OMDA) with a Buy rating.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Crexendo's Open Strategy Pays Off, Analyst Praises 'Disruptive Pricing Model'

Crexendo Inc (NASDAQ:CXDO) appears poised to gain share in the wholesale UCaaS (United Communications as a Service) market, according to Needham.

Benzinga

Dayforce: Native Platform To Drive Deal Growth, Says Bullish Analyst

Dayforce Inc (NYSE:DAY) offers a natively built platform that could drive more deals through human capital management partners, a Needham analyst says.

Benzinga

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

International Business Times UK

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

Barchart

Analysts: 1 Thing Apple Could Do to Make AAPL Stock a Buy Again Now

A rare downgrade from Needham urges Apple to tap into advertising as a new growth engine amid slowing earnings, rising competition, and valuation concerns.

Barchart

Apple Just Got a Rare Downgrade. Should You Ditch AAPL Stock Now?

Apple's slowing growth, rising tariffs, and AI lag could crack its trillion-dollar armor.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations